Skip to content

Study · Non-randomized trial · 1981

3 results

Acute hormonal effects on carnitine metabolism in thin and obese subjects: responses to somatostatin, glucagon, and insulin.

Genuth SM, Hoppel CL

Metabolism: clinical and experimental1 Apr 1981Cited by 18 (Europe PMC)

PMID6111018 (opens in a new tab)DOI10.1016/0026-0495(81)90121-9 (opens in a new tab)PepBankPUB-06111018
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In thin and obese subjects, adding glucagon to somatostatin reversed hyperketonemia after 2 hr.

    In plain wordsIn thin and obese subjects, adding glucagon to somatostatin reversed high ketone levels after 2 hr compared with somatostatin alone.

    Peptide
    Glucagon
    Outcome
    DecreaseHyperketonemia
    Study

    n: not reported in source

    Comparator
    Somatostatin alone
    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When hyperglucagonemia was created by inclusion of glucagon with the somatostatin, the hyperketonemia was reversed after 2 hr and the increase in acylcarnitine abolished.
    2 context sentences
    Summary · context
    Plasma free carnitine and acylcarnitines were determined in man during acutely induced insulin deficiency.
    Summary · context
    Qualitatively and quantitatively comparable results were seen in seven obese subjects.
  2. 02HumanNon-randomized trialActivity measurement

    In thin and obese subjects, adding glucagon to somatostatin abolished the increase in acylcarnitine.

    In plain wordsIn thin and obese subjects, adding glucagon to somatostatin prevented the acylcarnitine increase compared with somatostatin alone.

    Peptide
    Glucagon
    Outcome
    DecreaseAcylcarnitine increase
    Study

    n: not reported in source

    Comparator
    Somatostatin alone
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When hyperglucagonemia was created by inclusion of glucagon with the somatostatin, the hyperketonemia was reversed after 2 hr and the increase in acylcarnitine abolished.
    2 context sentences
    Summary · context
    Plasma free carnitine and acylcarnitines were determined in man during acutely induced insulin deficiency.
    Summary · context
    Qualitatively and quantitatively comparable results were seen in seven obese subjects.
  3. 03HumanNon-randomized trialActivity measurement

    In thin and obese subjects, adding glucagon to somatostatin accentuated the decrease in free carnitine.

    In plain wordsIn thin and obese subjects, adding glucagon to somatostatin increased the fall in free carnitine compared with somatostatin alone.

    Peptide
    Glucagon
    Outcome
    DecreaseFree carnitine decrease
    Study

    n: not reported in source

    Comparator
    Somatostatin alone
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, the decrease in free carnitine was accentuated.
    3 context sentences
    Summary · context
    When hyperglucagonemia was created by inclusion of glucagon with the somatostatin, the hyperketonemia was reversed after 2 hr and the increase in acylcarnitine abolished.
    Summary · context
    Plasma free carnitine and acylcarnitines were determined in man during acutely induced insulin deficiency.
    Summary · context
    Qualitatively and quantitatively comparable results were seen in seven obese subjects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.